Nausea Clinical Trial
— AVERTOfficial title:
Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen
Verified date | December 2017 |
Source | University of Vermont |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Severe nausea and/or vomiting in patients receiving radiotherapy to the upper abdomen is common despite having received pre-medication with ondansetron, a standard preventive treatment. This study aims to reduce the incidence of significant nausea and/or vomiting with the addition of the NK1-antagonist aprepitant to standard ondansetron treatment. This study will also assess the safety and tolerability of prolonged administration of aprepitant over the 4 to 6 week period of radiation treatment.
Status | Completed |
Enrollment | 52 |
Est. completion date | August 1, 2016 |
Est. primary completion date | July 1, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Any patient with a diagnosis of malignancy localized to the upper abdomen and requiring chemoradiation or radiation alone. 2. Receiving standard-fractionation radiation therapy (> 40 Gy) 3D-conformal radiation therapy or IMRT to a field involving the upper abdomen, either alone or combined with radiosensitizing 5FU, capecitabine, or gemcitabine permitted. 3. Age > 18 years old 4. Life expectancy >3 months 5. Performance status 0-2 inclusive 6. No more than mild to moderate hepatic impairment corresponding to Child-Pugh Class A or B, respectively (Child-Pugh score 5 to 9). See Appendix V for Child Pugh Classification. 7. Women of child-bearing potential and men must agree to use adequate contraception such as abstinence or effective barrier and/or non-hormonal contraception for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 8. Adequate organ reserve to include: Absolute Neutrophil Count = 1500/mcl , Hemoglobin = 8.0 g/dl, platelet count = 100,000/mcl, creatinine = 2.0, AST & ALT = 2.5 x ULN 9. Baseline ECG showing QTc value = 480 millisecond 10. Informed consent Exclusion Criteria: 1. Use of any other concomitant chemotherapy agent concurrently with radiation therapy aside from capecitabine, gemcitabine, or 5-fluorouracil (none of these agents are CYP 3A4 substrates). 2. Baseline vomiting is not controlled: Patients who have vomited or have nausea requiring antiemetic treatment within 24 hours prior to initiation of treatment. 3. Scheduled to receive treatment within 24 hours prior to day one or during the study periods with other potential or known antiemetic agents including but not limited to serotonin antagonists aside from ondansetron per study protocol, phenothiazines, butyrophenones, substituted benzamides, antihistamines, and cannabinoids. Chronically used benzodiazepines may be continued as a single nightly dose for sleep. 4. Any steroid use except topical steroids. Patients need to be off systemic steroid treatment for 7 days prior to start of chemoradiation therapy. 5. Uncontrolled CNS tumor 6. Other physical causes for nausea or vomiting (such as bowel obstruction) not related to chemoradiation administration 7. Hypersensitivity to either of the study agents 8. Planned simultaneous administration of any other investigational agents 9. Pregnant or nursing women 10. Patients taking other CYP3A4 inducers or inhibitors would be required to discontinue their use for at least 7 days prior to initiation of chemoradiation therapy. Examples of CYP3A4 inducers include aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, rifampin, and St. Johns Wort. Examples of CYP3A4 inhibitors include azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil. 11. CYP3A4 substrates are not contraindicated. However, patients taking CYP3A4 substrates should be cautioned to consult with their physician to minimize their use, if possible. Example substrates include benzodiazepines, calcium channel blockers, ranolazine, ergot derivatives, mirtazapine, nateglinide, tacrolimus, and venlafaxine. 12. Concomitant use of pimozide, terfenadine, cisapride, and astemizole is contraindicated per the Emendâ„¢ [10] product circular as dose-dependent inhibition of CYP 3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious and life-threatening reactions. Patients taking these medications ineligible to participate in this study unless they are discontinued for at least 7 days prior to start of aprepitant. 13. Warfarin: Aprepitant may increase warfarin metabolism and the INR may be decreased. Twice weekly monitoring of INR recommended in the first 2-week period of radiation followed by weekly monitoring in subsequent weeks until discontinuation of aprepitant. Twice weekly monitoring is again recommended after aprepitant discontinuation until INR has stabilized. 14. Contraceptives (estrogens and progestins): Aprepitant may decrease the plasma levels of estrogen and progestin contraceptives. Contraceptive efficacy may be reduced. A nonhormonal form of contraception is necessary during treatment and for 1 month following the last dose of aprepitant. |
Country | Name | City | State |
---|---|---|---|
United States | Fletcher Allen Health Care | Burlington | Vermont |
United States | Mayo Clinic Arizona | Scottsdale | Arizona |
United States | Wake Forest Baptist Health | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of Vermont | Mayo Clinic, Norris Cotton Cancer Center, University of Massachusetts, Worcester, Wake Forest University Health Sciences |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete Response rate (no vomiting and no rescue anti-emetic therapy) | overall period of radiation treatment (4-8 weeks) | ||
Secondary | Complete Response rate | Cumulatively increasing time intervals from the start of radiation therapy (7 days, 14 days, 21 days, 28 days, 35 days, 42 days) | ||
Secondary | Proportion of patients who did not vomit | Overall period of radiation therapy (4-8 weeks) | ||
Secondary | No Significant Nausea: The proportion of patients who did not experience any nausea = 3 on 0 - 10 scale | Overall period of radiation treatment (4-8 weeks) | ||
Secondary | No Nausea: The proportion of patients who did not experience any nausea. Nausea = 0 on 0 - 10 scale | Overall period of radiation treatment (4-8 weeks) | ||
Secondary | Complete Protection: The proportion of patients who did not vomit, require rescue therapy, or have nausea = 3 on 0 - 10 scale | Overall period of radiation treatment (4-8 weeks) | ||
Secondary | Total Protection: The proportion of patients who did not vomit, require rescue therapy, or have any nausea (Nausea = 0 on 0 - 10 scale). | Overall period of radiation treatment (4-8 weeks) | ||
Secondary | Vomiting frequency: The frequency of vomiting (# episodes per week) in patients who did vomit at least once. | Overall period of radiation treatment (4-8 weeks) | ||
Secondary | Nausea frequency: The frequency of nausea (Nausea > 0 in a given week/ number of weeks during overall period of radiation treatment) | Overall period of radiation treatment (4-8 weeks) | ||
Secondary | Significant Nausea frequency: The frequency of significant nausea (Nausea = 3 in a given week/ number of weeks during overall period of radiation treatment) | Overall period of radiation treatment (4-8 weeks) | ||
Secondary | Frequency of rescue medication use: The number of days in which rescue medication was taken / number of days of radiotherapy | overall period of radiation treatment (4-8 weeks) | ||
Secondary | Time to Failure: The time period in days from the start of radiation until the first vomiting episode or use of rescue medication for all patients and for the subset of patients who do not have a Complete Response. | Overall period of radiation treatment (4-8 weeks) | ||
Secondary | All adverse events that occur during radiation treatment with assessment of severity (CTC v.3) and relationship to study drug. | Overall period of radiation treatment (4-8 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01649258 -
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
|
Phase 1 | |
Completed |
NCT02939287 -
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
|
Phase 3 | |
Not yet recruiting |
NCT06055192 -
Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
|
||
Recruiting |
NCT04091789 -
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
|
Phase 2 | |
Completed |
NCT02462811 -
A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)
|
Phase 3 | |
Completed |
NCT01007500 -
Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery
|
Phase 4 | |
Recruiting |
NCT00528554 -
Laser Acupuncture Against Nausea in Children
|
N/A | |
Completed |
NCT00537875 -
Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens
|
N/A | |
Completed |
NCT00394966 -
A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)
|
Phase 2 | |
Completed |
NCT00947128 -
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions
|
Phase 1 | |
Completed |
NCT00946387 -
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions
|
Phase 1 | |
Recruiting |
NCT05433636 -
Mindful Waiting Room
|
N/A | |
Not yet recruiting |
NCT04827108 -
Psychometric Properties of the Chinese Version of PeNAT
|
||
Not yet recruiting |
NCT04853303 -
VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK
|
N/A | |
Terminated |
NCT04247100 -
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
|
N/A | |
Recruiting |
NCT04181346 -
Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting
|
Phase 2 | |
Recruiting |
NCT03679182 -
Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care
|
Phase 2 | |
Completed |
NCT02618343 -
EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
|
N/A | |
Terminated |
NCT01405924 -
Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)
|
Phase 2 | |
Recruiting |
NCT04116697 -
A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan
|
N/A |